Literature DB >> 22393122

Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus.

Haiyan Liu1, Li Liu, Jia Li, Dan Mei, Ru Duan, Nan Hu, Haifang Guo, Zeyu Zhong, Xiaodong Liu.   

Abstract

The purpose of this study was to evaluate the contributions of impaired cytochrome P450 and breast cancer resistance protein (BCRP) activity and expression to drug pharmacokinetics under diabetic conditions. Diabetes was induced in rats with the intraperitoneal administration of streptozocin. Glibenclamide (GLB), a substrate of BCRP, served as a model drug. The pharmacokinetics of orally administered GLB (10 mg/kg) were studied. The results showed that diabetes mellitus significantly increased exposure (area under the curve and peak concentration) to GLB after oral administration. Data from hepatic microsomes suggested impairment of GLB metabolism in diabetic rats. GLB metabolism in hepatic microsomes was significantly inhibited by a selective inhibitor (sulfaphenazole) of CYP2C11 and an anti-CYP2C11 antibody. Western blotting further indicated the contribution of impaired CYP2C11 expression to the impairment of GLB metabolism. Excretion data showed that ∼72% of the orally administered dose was excreted in the feces of normal rats, which indicates an important role for intestinal BCRP. Diabetes significantly decreased the recovery from feces, which was only 40% of the orally administered dose. Results from in situ, single-pass, intestinal perfusion experiments revealed that diabetes significantly increased the apparent effective permeability and decreased the efflux of GLB through the intestine; this suggests impairment of intestinal BCRP function, which may play a role in the increased exposure to orally administered GLB in diabetic rats. Insulin treatment partly or completely reversed the changes in diabetic rats. All results yielded the conclusion that impaired hepatic CYP2C11 and intestinal BCRP expression and activity induced by diabetes contributed to the increased exposure of orally administered GLB.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22393122     DOI: 10.1124/dmd.111.043513

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.

Authors:  Dan Xu; Feng Li; Mian Zhang; Ji Zhang; Can Liu; Meng-yue Hu; Ze-yu Zhong; Ling-ling Jia; Da-wei Wang; Jie Wu; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

3.  Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

Authors:  Jia Li; Hai-Fang Guo; Can Liu; Zeyu Zhong; Li Liu; Xiao-Dong Liu
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

4.  Altered glycaemia differentially modulates efflux transporter expression and activity in hCMEC/D3 cell line.

Authors:  Ravi K Sajja; Luca Cucullo
Journal:  Neurosci Lett       Date:  2015-05-14       Impact factor: 3.046

5.  The NACHT, LRR and PYD Domains-Containing Protein 3 (NLRP3) Inflammasome Mediates Inflammation and Voiding Dysfunction in a Lipopolysaccharide-Induced Rat Model of Cystitis.

Authors:  Francis M Hughes; James G Kennis; Melissa N Youssef; Danielle W Lowe; Brooke E Shaner; J Todd Purves
Journal:  J Clin Cell Immunol       Date:  2016-02-29

Review 6.  Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

7.  The NLRP3 Inflammasome Mediates Inflammation Produced by Bladder Outlet Obstruction.

Authors:  Francis M Hughes; Hayden M Hill; Case M Wood; Andrew T Edmondson; Aliya Dumas; Wen-Chi Foo; James M Oelsen; Goran Rac; J Todd Purves
Journal:  J Urol       Date:  2015-12-18       Impact factor: 7.450

8.  Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats.

Authors:  Li Liu; Ming-xing Miao; Ze-yu Zhong; Ping Xu; Yang Chen; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

9.  Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine.

Authors:  Qiu-Shi Xie; Jia-Xin Zhang; Ming Liu; Pei-Hua Liu; Zhong-Jian Wang; Liang Zhu; Ling Jiang; Meng-Meng Jin; Xiao-Nan Liu; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2020-06-17       Impact factor: 6.150

Review 10.  Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Authors:  Lucy Darakjian; Malavika Deodhar; Jacques Turgeon; Veronique Michaud
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.